Cellular calcium signaling plays important roles in several signal transduction pathways that control proliferation, differentiation and apoptosis. In epithelial cells calcium signaling is initiated mainly by calcium release from endoplasmic reticulum-associated intracellular calcium pools. Because calcium is accumulated in the endoplasmic reticulum by Sarco/Endoplasmic Reticulum Calcium ATPases (SERCA), these enzymes play a critical role in the control of calcium-dependent cell activation, growth and survival. We investigated the modulation of SERCA expression and function in human lung adenocarcinoma cells. In addition to the ubiquitous SERCA2 enzyme, the SERCA3 isoform was also expressed at variable levels. SERCA3 expression was selectively enhanced during cell differentiation in lung cancer cells, and marked SERCA3 expression was found in fully differentiated normal bronchial epithelium. As studied by using a recombinant fluorescent calcium probe, induction of the expression of SERCA3, a lower calcium affinity pump, was associated with decreased intracellular calcium storage, whereas the amplitude of capacitative calcium influx remained unchanged. Our observations indicate that the calcium homeostasis of the endoplasmic reticulum in lung adenocarcinoma cells presents a functional defect due to decreased SERCA3 expression that is corrected during pharmacologically induced differentiation. The data presented in this work show, for the first time, that endoplasmic reticulum calcium storage is anomalous in lung cancer cells, and suggest that SERCA3 may serve as a useful new phenotypic marker for the study of lung epithelial differentiation.
Introduction
Non-small cell lung cancer is currently the most frequent fatal malignancy worldwide with more than a million deaths occurring annually [1, 2] . Although much is known about risk factors such as tobacco smoking, or regarding molecular and genetic events that occur during lung tumorigenesis, the overall survival rate of lung cancer could not be significantly improved during the last thirty years [2] . This indicates that currently available knowledge of the molecular biological behavior of lung carcinoma cells is insufficient for the development of efficient therapy. In particular, knowledge about calcium signaling in lung cancer cells is scarce, although calcium signaling is an essential component of several regulatory networks involved in the control of cell growth, differentiation and apoptosis.
Calcium-dependent cell activation is initiated by the release of calcium ions stored in the endoplasmic reticulum (ER) into the cytosol through inositol-1,4,5-trisphosphate receptor calcium channels [3] . In addition, calcium in the ER lumen is required for the function of various ER located chaperones such as calreticulin or calnexin involved in the conformational maturation and posttranslational modification of newly synthesized proteins that transit through the organelle [4] [5] [6] . Abnormal endoplasmic reticulum calcium homeostasis can lead to cellular stress responses, growth arrest and apoptosis [4, [7] [8] [9] .
Sarco/Endoplasmic Reticulum Calcium ATPases (SERCA) enzymes are essential for the dynamic equilibrium of ER calcium homeostasis. Located in the ER membrane, these enzymes sequester calcium ions from the cytosol into the ER lumen by ATP-dependent active ion transport, and thus generate a steep calcium concentration gradient between the cytosol (approximately 50-100 nM) and the ER lumen (approximately 0.1 mM) [10] . SERCA proteins are encoded by three genes (ATP2A1, 2 and 3), that can give rise to several protein 4 isoforms by alternative splicing [11] [12] [13] [14] [15] . SERCA expression is tissue dependent and developmentally regulated. SERCA1 is expressed in skeletal muscle, and the SERCA2a isoform is mainly expressed in cardiomyocytes. Whereas SERCA2b is a ubiquitously expressed isoform thought to be involved in "housekeeping" functions, in several cell types such as cells of hematopoietic origin, gastric and colonic epithelial cells, β-cells of islets of Langerhans or vascular endothelium, SERCA2b has been shown to be co-expressed with SERCA3 [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Because SERCA2b and SERCA3 enzymes display distinct calcium affinities [27] [28] [29] [30] [31] [32] , their co-expression is involved in the fine-tuning of the parameters of ER calcium sequestration according to the specific calcium storage and release requirements of the ER of a given cell type.
By controlling intra-ER calcium levels, SERCA enzymes are involved in the control of cell growth [33] [34] [35] [36] . Small molecular SERCA inhibitors are tumor promoters [37, 38] , and SERCA mutations have been identified in cancer [39] [40] [41] [42] [43] . In this context we have previously reported that the expression of SERCA enzymes is anomalous in breast, colon, as well as gastric carcinoma due to the loss of expression of SERCA3 [18, 44, 45] . It has also been shown that SERCA3 expression is induced during histone-deacetylase inhibitor-induced differentiation of gastric and colon carcinoma cells [18] , as well as following the inhibition of the APC/β-catenin/TCF4 axis [44] , and that normal colonic and gastric epithelium express SERCA3 abundantly [44] . In addition, the pharmacological modulation of SERCA activity has also been shown to enhance cell differentiation in colon carcinoma [44] and acute promyelocytic leukemia [46] cells. Taken together, these observations indicate that the functional maturation of ER calcium homeostasis that occurs during normal cell differentiation is blocked due to deficient SERCA3 expression in malignant cells, and that this phenomenon is involved in the maintenance of the neoplastic phenotype [16, 47] .
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In order to establish whether defects of ER calcium homeostasis can be found in pulmonary neoplasia, in this work we investigated SERCA expression in normal lung in situ and in lung adenocarcinoma cell lines undergoing pharmacologically induced cell differentiation in vitro, and investigated functional calcium storage capacity by confocal microscopic calcium fluorimetry using a green fluorescent protein-based calcium probe in differentiated and control cells. Our results indicate that SERCA3 is abundantly expressed in normal fully differentiated bronchial epithelium, whereas expression is highly heterogeneous in carcinoma tissue. We also show that SERCA3 expression is induced during the pharmacologically induced differentiation of lung adenocarcinoma cell lines, and that differentiation induction leads to decreased ER calcium storage.
These observations show that similarly to other types of neoplasia, lung cancer cell calcium homeostasis can also be remodeled during drug-induced cell differentiation. This indicates that defects of SERCA3 expression in cancer may be a widespread phenomenon, and show, for the first time that endoplasmic reticulum calcium homeostatic defects are involved in shaping the lung cancer phenotype.
Results

SERCA expression in lung tumor cell lines and primary tumor tissue
Western immunoblot analysis performed on equal amounts of proteins obtained from total cell lysates from various non-small cell lung carcinoma cell lines indicates that the SERCA expression pattern of these cells is heterogeneous. As shown in Figure 1 Panel A, whereas all cell lines express the ubiquitous SERCA2 isoenzyme, SERCA3 expression displays a marked heterogeneity: whereas in cell lines such as HCC-827 or NCI-H441, SERCA3 protein expression is barely detectable or absent, in other cell lines such as Calu-3,
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A-427, NCI-H23, A549, Cha-Go K-1, NCI-H1650, NCI-H358 or NCI-H460, SERCA3 protein is highly expressed and expression levels vary depending on cell line.
When investigated in situ by immunohistochemistry using a SERCA3-specific monoclonal antibody, SERCA3 expression could be detected in normal ciliated bronchial epithelium and, to a variable degree also in primary human lung adenocarcinoma tissue. As shown in Figure 1 These observations taken together show that SERCA3 expression is part of the normal differentiation program of lung epithelium, and that SERCA3 expression may be decreased or lost in lung adenocarcinoma. In addition, these observations indicate that heterogeneous SERCA3 expression in lung cancer cell lines in vitro reflects a pathophysiologically relevant phenomenon, because this is also observed in tumour tissue in situ.
Induction of SERCA expression by short chain fatty acids
When various non-small cell lung carcinoma cell lines were subjected to treatments with short chain fatty acids and analogs, a selective induction of SERCA3 expression could be observed. As shown in Figure 2 , treatment with 5 mM phenylbutyrate for 5 days resulted in a marked and selective up-regulation of the expression of the SERCA3 isoenzyme, whereas the expression of SERCA2 was not modified significantly or was decreased. SERCA3 induction could also be obtained by n-butyrate or n-valerate as well (not shown). As studied in the A549 cultures [50] . The cells form a tight, polarized monolayer that displays trans-epithelial electrical resistance, barrier function, vectorial solute transport, as reflected by the formation of domes when grown on plastic, and express apical microvilli and tight junctional complexes [51] . Post-confluent Calu-3 cells are widely used in pharmacological research as an in vitro model for bronchial epithelium [52] . As shown in Figure 5 , the expression of SERCA3 is markedly increased in Calu-3 cells after confluency, whereas SERCA2 expression is not modified significantly. Interestingly, short-chain fatty acid treatment of confluent Calu-3 led to a further increase of SERCA3 expression. Phenylbutyrate has already been shown to enhance CFTR protein expression in post-confluent, differentiated Calu-3 cells [52] . These data, when taken together indicate that the induction of SERCA3 expression takes place during the spontaneous differentiation of post-confluent Calu-3 cells, a process that can be further enhanced by phenylbutyrate. 
Discussion
Because calcium uptake into the ER is performed exclusively by SERCA enzymes, SERCA function constitutes a key nodal point in cellular calcium homeostasis and signaling.
SERCA activity is required for calcium accumulation in a resting cell for intra-ER calcium dependent chaperone functions, as well as for calcium accumulation in the ER for inositol-1,4,5-trisphosphate-induced calcium release during cell activation. Moreover, because SERCA enzymes take up calcium from the cytosol even during an inositol-1,4,5-trisphosphate-induced calcium-release event, they can shape the amplitude and the duration of calcium peaks, or modulate the spatiotemporal characteristics of calcium oscillations in the cytosol. SERCA activity can therefore critically modulate the state of activation of a cell, and can influence the type and the amplitude of the response given by a cell to calcium-dependent stimuli. This has important consequences for tumor biology: direct pharmacological SERCA inhibitors such as thapsigargin or 2,5-di-tert-butyl-1,4-benzohidroquinone are known tumor promoters, and SERCA2 +/-knock-out is known to lead to squamous tumorigenesis with a long incubation time. In addition, sequencing of the SERCA2 and SERCA3 genes in various tumors including lung cancer and corresponding normal tissue suggests that inactivating mutations occur in these genes in a proportion of tumors [40, 41] , and it has thus been suggested that SERCA3 haploinsufficiency may predispose to cancer development, or may 10 promote tumor progression [41, 42] . In this context the induction of SERCA3 expression, as observed in our work, may therefore exert anti-oncogenic effects in lung epithelial cells. The normal lung contains several distinct and specialized epithelial cell types. In addition, lung carcinoma as a group consists of several histological tumor types that can display different degrees of histological differentiation. The ontogenic relationship between normal and tumoral cell types in the lung is not established in sufficient detail [1] , and the molecular signaling mechanisms involved in the induction and the maintenance of tumoral 11 phenotypes of increasing malignancy are not sufficiently known in the lung. Consequently, lung cancer is currently not amenable to successful pharmacological intervention. The observation that lung cancer cell calcium ER homeostasis is remodeled during differentiation is important for cancer biology because this indicates that lung adenocarcinoma cells may display calcium homeostatic defects similar to those observed in colon, gastric and breast carcinoma, as well as acute promyelocytic leukemia. In those systems the cross-talk of ER calcium homeostasis with other mechanisms of control of cell differentiation permits to induce and potentiate pharmacologically induced cell differentiation and to overcome certain forms of resistance to differentiation-induction therapy in vitro [44, 46] . In addition, SERCA3 expression has also been shown to be a useful new immunohistochemical marker for the study of the state of differentiation and degree of malignancy of colon and breast tumors [44, 45] .
Data presented in this paper indicate, for the first time, that ER calcium biology is connected to cell differentiation also in pulmonary epithelium, and shows that ER calcium homeostasis presents defects in lung cancer cells, which can be overcome by pharmacologically induced cell differentiation. Although the precise correlation of the loss of SERCA3 expression with lung adenocarcinoma histological type, grade, molecular subtypes or clinical parameters requires further work, the demonstration of calcium homeostatic anomalies in lung cancer may help identify new calcium-dependent targets for the therapy of the disease. In addition, our observations suggest that SERCA3 may prove useful for the immunohistochemical analysis of lung tumors and for the study of bronchic epithelial differentiation.
Materials and Methods
Chemicals
n-butyric and n-valeric, 4-phenylbutyric acid, as well as sodium acetate, sodium caproate, sodium valproate, isobutyric, 4-methylvaleric, as well as phenylacetic, 3-phenylpropionic and 5-phenylvaleric acids were from Sigma-Aldrich (Saint-Quentin Fallavier, France). Free acids were dissolved to 300 mM final concentration in 300 mM sterile sodium bicarbonate solution, filtered through 0.2 µm membranes and stored at -25°C. Sodium salts were dissolved at 300 mM concentration in sterile water and filtered through 0.2 µm membranes.
Cell lines
The Calu-3, NCI-H23, NCI-H358, NCI-H441, NCI-H460, NCI-H596, NCI-H1299 and NCI-H1650, as well as the HCC-827 cell lines were obtained from ATCC (ATCC-LGC Standards Sarl, Molsheim, France). A549 and A427 cells were from DSMZ (Braunschweig, Germany), and Cha-Go K1 was purchased from ECACC (Porton Down, UK). The various cell lines were cultured according to the instructions of the cell line depository of origin.
RPMI-based media contained Ultraglutamine-I (Lonza, Verviers, Belgium) in addition to 2 mM glutamine.
Treatments
Exponentially growing cells were trypsinized and plated into 60cm² cell culture grade Petri dishes in new medium. When cultures reached 40-60% confluency as examined by light microscopy, medium was renewed and drugs were added from concentrated stock solutions.
Following treatments as indicated in Figures, cells were washed with ice-cold 150 mM NaCl
and precipitated with 5% trichloroacetic acid (TCA). TCA pellet was quantified and dissolved in modified Laëmmli-type sample buffer exactly as described earlier [17] , and 50 µg total cellular protein was deposited for SDS-polyacrylamide gel electrophoresis per well [17] .
Following electrophoresis and transfer to nitrocellulose membranes, equal loading of samples was controlled prior immunoblotting by Ponceau red staining of total protein deposited on the 13 membranes. Ponceau red stained blots were scanned and equal protein loading was controlled by densitometry using the ScionImage software (Scion Corp. CA) as described earlier in detail [17] .
Western blotting
The PLIM430 anti-SERCA3 mouse monoclonal antibody was used for Western immunblotting as hybridoma supernatant as described earlier in detail [17, 18, 44] . Purified mouse anti-gelsolin antibody (Cat # 610412, BD Transduction Laboratories, San José, CA, dissolved in TBS-milk at 0.05 µg/ml final concentration), and the mouse monoclonal anti-p21 antibody SC-71811 (Santa Cruz Biotechnologies, CA, dissolved in TBS-milk at 0.2 µg/ml final concentration) were used on heat treated samples (100°C for 12 min) run in 8% polyacrylamide gels. Antibodies were revealed with an anti-mouse Ig-horseradish peroxydase conjugate (Jackson Immuno-Research, Newmarket, Suffolk, UK) and the Enhanced Chemiluminescence system of Amersham (Courtaboeuf, France) as described earlier [17, 18, 44] . Non-saturated luminograms were scanned and densitometric analysis was done with the ScionImage software [11] [12] [13] [14] [15] .
Immunohistochemistry
Formalin fixed paraffin embedded lung cancer tissue microarray slides were purchased from BioChain Institute, Hayward, CA (T8235724, T8235732, Z7020066, Z7020067, CliniSciences, Montrouge, France) and from US Biomax, Rockville, MD (BC04015, BC041114, BC041115, BC04119b, LC20810, Euromedex, Souffelweyersheim, France).
Staining for SERCA3 was performed using the clone 2H3 monoclonal mouse anti-SERCA3 antibody (IgG2a kappa) from Abnova (Tebu-bio, Le Perray en Yvelines, France) raised against a GST-tagged peptide sequence encompassing the 501-621 amino acid fragment of 14 SERCA3, at 3 µg/ml final concentration diluted in Dako REAL TM antibody diluent (Dako France S.A.S., Trappes, France) as described in [45] . Briefly, after inhibition of endogenous peroxydase and antigen retrieval of deparaffinized sections by a tris-hidroxymethylaminomethane-based reagent (CC1 solution, Ventana Medical Systems, Illkirch, France) at 95-100°C for 12 minutes, slides were incubated for 30 minutes at 37°C with the antibody, and staining was revealed using the Ventana I-View Biotin-Ig-streptavidin-biotin-horseradish peroxydase system with blocking of endogenous biotin activity and copper enhancement, according to the instructions of the manufacturer. As negative control, isotype matched irrelevant antibody was used at the same concentration, and this gave no staining. As internal positive control, lymphocytes and vascular endothelial cells present in the samples and which express high levels of SERCA3 [17, 24] , were used. Slides were counterstained with hematoxylin and bluing agent (Ventana). SERCA3 immunostaining of the samples was evaluated semi-quantitatively using a four grade scale (0 to 3+). Photomicrographs were taken with a Zeiss Axio Scope.A1 microscope equipped with a Zeiss N-Achroplan 40x/0.65 objective and an AxioCam ICc1 camera, using the Axiovision 4.8.2 software. Tissue microarray slides were also processed using the ImmPRESS TM biotin-free polymerized enzyme staining system (Vector Laboratories, Clinisciences SAS, Nanterre, France) according to the instructions of the manufacturer, and SERCA3 staining with this system gave identical results.
Confocal fluorescent microscopic calcium measurements
In order to generate the SB-CAG-GCaMP2 fluorescent calcium probe, a DNA fragment encoding GCaMP2 was first generated by PCR using the pN1-GCaMP2 plasmid, a generous gift of Junichi Nakai, RIKEN Brain Science Institute, Saitama, Japan [53] . Primer sequences were as follows: forward, 5'-CTACCGGTCTCGCCACCAATG-3'; and reverse, 15 5'-AGATCTCCGCTCACTTCGCTGTC-3'. The forward primer adds an AgeI restriction site, the reverse primer adds a BglII restriction site. The complete GCaMP2 DNA-fragment was cloned via AgeI(5')/BglII(3') into a SB-CAG-AmaxaGFP vector from which Amaxa GFP was excised with the same enzyme pair. The GCaMP2 fragment is framed in the resulting vector by two left inverted repeat-direct repeat (IRDR) regions, which are the recognition motifs of Sleeping Beauty (SB) transposase [54] [55] [56] [57] , and possesses a CAG [58] promoter. The efficiency of such a symmetrical transposon was proven by T. Orbán (personal communication). This construct was used for stable transfection using the SB transposon delivery system as described earlier in detail [54] [55] [56] [57] 59 ]. For the SB transposase, we used an enhanced version of the enzyme having an approximately hundred-fold higher activity than the originally reconstructed transposase [59, 60] . For transfection of exponentially growing A549 cells, the FuGENE Maximal induction of SERCA3 expression is observed with valerate and phenylbutyrate.
